ATE517347T1 - Diagnose von leiden in zusammenhang mit verminderter arginin-bioverfügbarkeit - Google Patents
Diagnose von leiden in zusammenhang mit verminderter arginin-bioverfügbarkeitInfo
- Publication number
- ATE517347T1 ATE517347T1 AT05853035T AT05853035T ATE517347T1 AT E517347 T1 ATE517347 T1 AT E517347T1 AT 05853035 T AT05853035 T AT 05853035T AT 05853035 T AT05853035 T AT 05853035T AT E517347 T1 ATE517347 T1 AT E517347T1
- Authority
- AT
- Austria
- Prior art keywords
- arginine
- diagnosis
- decrease
- conditions related
- bioavailability
- Prior art date
Links
- 239000004475 Arginine Substances 0.000 title abstract 6
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 title abstract 6
- 238000003745 diagnosis Methods 0.000 title abstract 3
- 102000004452 Arginase Human genes 0.000 abstract 1
- 108700024123 Arginases Proteins 0.000 abstract 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 abstract 1
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 abstract 1
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 abstract 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 abstract 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 abstract 1
- 229960002173 citrulline Drugs 0.000 abstract 1
- 235000013477 citrulline Nutrition 0.000 abstract 1
- 230000003247 decreasing effect Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000004060 metabolic process Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 229960003104 ornithine Drugs 0.000 abstract 1
- 238000004393 prognosis Methods 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6806—Determination of free amino acids
- G01N33/6812—Assays for specific amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/978—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/12—Pulmonary diseases
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/12—Pulmonary diseases
- G01N2800/122—Chronic or obstructive airway disorders, e.g. asthma COPD
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/22—Haematology
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/22—Haematology
- G01N2800/224—Haemostasis or coagulation
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
- Y10T436/106664—Blood serum or blood plasma standard or control
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/17—Nitrogen containing
- Y10T436/171538—Urea or blood urea nitrogen
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/17—Nitrogen containing
- Y10T436/177692—Oxides of nitrogen
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Bioinformatics & Computational Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US63257204P | 2004-12-01 | 2004-12-01 | |
| PCT/US2005/043998 WO2006060793A2 (en) | 2004-12-01 | 2005-12-01 | Diagnosis of conditions associated with decreased arginine bioavailability |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE517347T1 true ATE517347T1 (de) | 2011-08-15 |
Family
ID=36565851
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT05853035T ATE517347T1 (de) | 2004-12-01 | 2005-12-01 | Diagnose von leiden in zusammenhang mit verminderter arginin-bioverfügbarkeit |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US7648840B2 (de) |
| EP (1) | EP1825261B1 (de) |
| AT (1) | ATE517347T1 (de) |
| CA (1) | CA2587647C (de) |
| WO (1) | WO2006060793A2 (de) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1596854A4 (de) | 2003-02-14 | 2007-06-06 | Childrens Hosp & Res Ct Oak | Behandlung von erkrankungen im zusammenhang mit verringerter stickoxid-bioverfügbarkeit, einschliesslich erhöhte arginase |
| WO2006060793A2 (en) * | 2004-12-01 | 2006-06-08 | Children's Hospital & Research Center At Oakland | Diagnosis of conditions associated with decreased arginine bioavailability |
| GB0612669D0 (en) * | 2006-06-27 | 2006-08-09 | Univ Leeds | Biomarkers for preeclampsia |
| EP2409157B1 (de) * | 2009-03-20 | 2015-11-04 | The Cleveland Clinic Foundation | Citrullin als risikoindikator für herz-kreislauf-erkrankung |
| WO2010147952A1 (en) * | 2009-06-15 | 2010-12-23 | The Cleveland Clinic Foundation | Methylated arginine metabolites as risk predictors of cardiovascular disease |
| WO2012158518A1 (en) * | 2011-05-13 | 2012-11-22 | The Penn State Research Foundation | Treatment of renal injury |
| WO2015179952A1 (en) * | 2014-05-26 | 2015-12-03 | Mcmaster University | A metabolite panel for improved screening and diagnostic testing of cystic fibrosis |
| CN109154621B (zh) * | 2016-05-17 | 2022-08-05 | 国立大学法人大阪大学 | 肾脏病的预后预测方法及系统 |
| US11655210B2 (en) | 2018-05-18 | 2023-05-23 | The General Hospital Corporation | Compound for improving L-arginine bioavailability |
| CU20200106A7 (es) | 2018-06-20 | 2021-08-06 | Axcella Health Inc | Composiciones y métodos para el tratamiento de hemoglobinopatías y talasemias |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4096037A (en) * | 1976-05-24 | 1978-06-20 | Pitman-Moore, Inc. | Arginase test |
| JPS6359899A (ja) * | 1986-09-01 | 1988-03-15 | Advance Co Ltd | 癌診断方法及びキツト |
| EP0441119A3 (en) | 1990-01-09 | 1992-10-14 | Richard D. Levere | The use of l-arginine in the treatment of hypertension and other vascular disorders |
| AU9797998A (en) | 1997-10-10 | 1999-05-03 | Trustees Of The University Of Pennsylvania, The | Compositions and methods for inhibiting arginase activity |
| WO1999043308A2 (en) | 1998-02-27 | 1999-09-02 | Marlene Rabinovitch | Treating pulmonary hypertension through tenascin suppression and elastase inhibition |
| US6784178B2 (en) | 2000-04-12 | 2004-08-31 | Cornell Research Foundation, Inc. | Pharmacotherapy for vascular dysfunction associated with deficient nitric oxide bioactivity |
| WO2002004465A1 (en) * | 2000-07-06 | 2002-01-17 | Fal Diagnostics | Methods and kits for the detection of arginine compounds |
| AU2001290879A1 (en) | 2000-09-15 | 2002-03-26 | California Institute Of Technology | Microfabricated crossflow devices and methods |
| US6686340B2 (en) * | 2001-06-19 | 2004-02-03 | Matthias Rath | Composition and method for prevention and treatment of health conditions caused by constriction of smooth muscle cells |
| EP1596854A4 (de) * | 2003-02-14 | 2007-06-06 | Childrens Hosp & Res Ct Oak | Behandlung von erkrankungen im zusammenhang mit verringerter stickoxid-bioverfügbarkeit, einschliesslich erhöhte arginase |
| WO2006060793A2 (en) * | 2004-12-01 | 2006-06-08 | Children's Hospital & Research Center At Oakland | Diagnosis of conditions associated with decreased arginine bioavailability |
-
2005
- 2005-12-01 WO PCT/US2005/043998 patent/WO2006060793A2/en not_active Ceased
- 2005-12-01 US US11/293,351 patent/US7648840B2/en active Active
- 2005-12-01 AT AT05853035T patent/ATE517347T1/de not_active IP Right Cessation
- 2005-12-01 EP EP05853035A patent/EP1825261B1/de not_active Expired - Lifetime
- 2005-12-01 CA CA2587647A patent/CA2587647C/en not_active Expired - Fee Related
-
2009
- 2009-12-01 US US12/628,841 patent/US8309320B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US20100196939A1 (en) | 2010-08-05 |
| EP1825261B1 (de) | 2011-07-20 |
| WO2006060793A2 (en) | 2006-06-08 |
| CA2587647A1 (en) | 2006-06-08 |
| US20060160236A1 (en) | 2006-07-20 |
| EP1825261A4 (de) | 2009-01-07 |
| CA2587647C (en) | 2017-03-28 |
| WO2006060793A3 (en) | 2006-12-28 |
| US7648840B2 (en) | 2010-01-19 |
| US8309320B2 (en) | 2012-11-13 |
| EP1825261A2 (de) | 2007-08-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201391627A1 (ru) | Анализ на наличие лизилоксидазоподобных белков 2 и способы его применения | |
| EP1953527A3 (de) | Probenanalysegerät und Computerprogrammprodukt | |
| ATE554389T1 (de) | Apex als marker für lungenkrebs | |
| WO2008070865A3 (en) | Materials and methods for efficient and accurate detection of analytes | |
| WO2007002579A3 (en) | Assay cartridges and methods for point of care instruments | |
| DK2021794T3 (da) | Anvendelse af protein S100A 12 som en markør for colorektal cancer | |
| EP2319941A3 (de) | Methode und vorrichtung zur korrelation von biomarker produktmengen mit krankheiten | |
| MX2013003038A (es) | Espectroscopia raman para operaciones de bioprocesos. | |
| ATE549624T1 (de) | Verfahren und zusammensetzungen zur diagnose und behandlung von grippe | |
| ATE517347T1 (de) | Diagnose von leiden in zusammenhang mit verminderter arginin-bioverfügbarkeit | |
| ATE532063T1 (de) | Elektrochemischer biosensor | |
| WO2007114986A3 (en) | Cooperative probes and methods of using them | |
| EP2212700B8 (de) | Verfahren zur beurteilung von kolorektalem krebs anhand einer stuhlprobe durch verwendung einer marker-kombination aus calprotectin und einem hämoglobin/haptoglobin-komplex | |
| WO2007134028A3 (en) | Biomarkers for depression and methods using the same | |
| EP2081029A3 (de) | Biomarker zur Diagnose diabetischer Retinopathie | |
| ATE375517T1 (de) | Diagnosestellung von akuten myokardialen, ischämischen erkrankungen durch kombination von markern | |
| EP2238431A4 (de) | Entwicklung und verwendung von cysteinmarkierten fluoreszierenden sonden aus ungebundenen analyten | |
| ATE443775T1 (de) | Hif-prolylhydroxylase-aktivitätstest | |
| WO2007084397A3 (en) | Processing of slpi by chymase | |
| NZ592819A (en) | Thyroid analyte detection and measurement | |
| WO2008131261A3 (en) | Peptide biomarkers of cardiovascular disease | |
| TR201900481T4 (tr) | Bağışıklık testi için aparat ve kit. | |
| WO2007103211A3 (en) | Methods to identify fat and lean animals using class predictors | |
| WO2010043393A8 (en) | Use of biglycan in the assessment of heart failure | |
| EA201100253A1 (ru) | Глутаминилциклаза в качестве диагностического/прогностического индикатора нейродегенеративных заболеваний |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |